US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% META $728.08 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% SPCX $158.96 ▲+0.00% JNJ $256.03 ▲+0.00%
FinancialContent

Sema4 Holdings Corp. - Warrant (NQ:SMFRW)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 0.0181 (200)
Ask (Size) 0.0260 (40)
Prev. Close 0.0240
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 105,429
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
From GeneDx Holdings Corp.
Via GlobeNewswire
News headline image
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Sema4|GeneDx President & Chief Executive Officer, Katherine Stueland, to deliver presentation 
From Sema4
Via GlobeNewswire

Performance

More News

Read More
News headline image
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
From Sema4
Via GlobeNewswire
News headline image
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
From Sema4
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bed Bath & Beyond, Sema4, Medtronic, and Palantir and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
From Sema4
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
From Sema4
Via GlobeNewswire
News headline image
Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns
From Sema4
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
From Sema4
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TuSimple, Kohl’s, Bed Bath & Beyond, and Sema4 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
From Sema4
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study
From Sema4
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR NOTICE: Sema4 Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SMFR; SMFRW
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Investor Alert: Sema4 Holdings Corp. (SMFR, SMFRW) Class Action - Bronstein, Gewirtz & Grossman, LLC, A Prominent Firm, Encourages Shareholders to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
EQUITY ALERT: Rosen Law Firm Encourages Sema4 Holdings Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SMFR, SMFRW
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Sema4 Holdings Corp. (SMFR, SMFRW) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm
Via ACCESSWIRE
News headline image
SEMA4 ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sema4 Holdings Corp. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
SEMA4 ALERT: Bragar Eagel & Squire, P.C. is Investigating Sema4 Holdings Corp. on Behalf of Sema4 Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire

Frequently Asked Questions

Is Sema4 Holdings Corp. - Warrant publicly traded?
Yes, Sema4 Holdings Corp. - Warrant is publicly traded.
What exchange does Sema4 Holdings Corp. - Warrant trade on?
Sema4 Holdings Corp. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for Sema4 Holdings Corp. - Warrant?
The ticker symbol for Sema4 Holdings Corp. - Warrant is SMFRW on the Nasdaq Stock Market